QTRX Quanterix Corporation

Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference and Appear on the June 3 Episode of The Bio Report

(NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10th at 3:50pm ET.

Attendees can access the public webcast at or by visiting the News & Events page within the Investors section of the Quanterix website at . Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

Additionally, Hrusovsky will appear on the June 3 episode of , a leading podcast that focuses on the intersection of biotechnology and business, science, and policy. The episode, which airs at 4:00 p.m., EDT, will be available to listen on demand at or through the following podcast providers: Apple Podcasts, iHeart Radio, Google Podcasts, Soundcloud, and Stitcher.

To learn more about Quanterix, visit:

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

EN
02/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Quanterix Corporation

 PRESS RELEASE

Quanterix Releases Operating Results for Third Quarter 202

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023. Third Quarter Financial Highlights Revenue was $31.3 million, an 18% increase from $26.6 million for the corresponding prior year period. GAAP gross margin was 56.8% as compared to 41.1% for the corresponding prior year period. Non-GAAP gross margin was 48.6% as compared to 34.9% for the corresponding prior year period. Net loss was $7.8 million as compared to $35.1 mill...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 16, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Quanterix Corp: 1 director

A director at Quanterix Corp bought 20,200 shares at 24.850USD and the significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 20, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch